TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pelvic Floor symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: maintenance of pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Control rates of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Control rates of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Control rates of hyperlipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of intracerebral injection of C134 virus
Endpoint domain: Adverse events/effects
Primary endpoint: Cough Impact Domain of the CASA-Q
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reactance at 5 Hertz (Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of ecopipam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of ecopipam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of ecopipam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical Activity Questionnaire for Older Children Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of clinically relevant primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Limit the progression to PTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of freedom from major adverse event (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients who agree to participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who complete all study procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adolescents' Mean Acceptability Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-efficacy of obese patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Birth Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Birth Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scale of Pain Expression during Childbirth (ESVADOPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin penetration into exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dose of opioid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Child PTSD Symptom Scale (CPSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Center for Epidemiological Studies Depression Scale (CES-DC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with recurrent laryngeal nerve injury
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with hypoparathyroidism
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with mental nerve injury
Endpoint domain: Adverse events/effects
Primary endpoint: Post-stroke function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: New ischemic stroke events
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events and serious adverse events during MAD period
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events and serious adverse events during LTE period
Endpoint domain: Adverse events/effects
Primary endpoint: circumferential bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: posterior bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain at energy level 900
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly Rate of ED and Hospital Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adequate growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who can enroll in CAR T-cell therapy study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Radioactivity - Plasma Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Radioactivity - Whole Blood Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pharmacokinetic Parameters Bemcentinib - Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical resilience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Endpoint domain: Adverse events/effects
Primary endpoint: Implant efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change over time in gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evidence of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic evidence of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without major or severe bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Spatiotemporal index (STI) of lip aperture during negative valence condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatiotemporal index (STI) of lip aperture during neutral valence condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in swallowing function at 3 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in swallowing function at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of imaging studies successfully superimposed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive Scale -2 (Y-BOCS-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VO2 Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Time required for administration of analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Uptake characteristics of [18F]CETO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain intensity based on Brief Pain Inventory (BPI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of adverse medication-related symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: ACR Pedi 30 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of free aflibercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of short term HMG-CoA reductase treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACC score of ≥2 grade from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical jump-related outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Posttraumatic Stress Related Functioning Inventory (PRFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative manifest spherical equivalent refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of treatment-emergent, drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of rehabilitation interventions accepted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Minimal residual disease (MRD)-negativity in complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degrees of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of index subjects achieving complete cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of adverse outcomes attributed to withholding antibacterials
Endpoint domain: Adverse events/effects
Primary endpoint: Total duration of antibacterial prescription for the index visit
Endpoint domain: Resource use
Primary endpoint: Time-weighted Sum of Pain Intensity Difference (SPID48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reversal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-∞) of Plasma N-Hydroxycitidine (NHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of Prednisone
Endpoint domain: Adverse events/effects
Primary endpoint: McGill Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D-5L Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Longitudinal change of SV95C (stride velocity 95th centile)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-ligation cardiac syndrome (PLCS) or death within 7 days of PDA closure
Endpoint domain: Mortality/survival
Primary endpoint: Change in mean Schirmer's test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Doxylamine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Pyridoxal-5-phosphate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t (Doxylamine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t (Pyridoxal-5-phosphate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf (Doxylamine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf (Pyridoxal-5-phosphate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Forced Vital Capacity (FVC) [% pred.]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in dyspnea symptom score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in cough symptom score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30-day Clinical NSQIP-defined serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Evolution of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean score of Feasibility of Intervention Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants with HIV RNA viral load < 200 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of adverse events and dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in annualized joint bleeding rate (AjBR) for treated and untreated bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of target joint development, resolution and/or recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity level of Autism Spectrum disorders (ASD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Biomarker (Microtubule associated proteins (MAPs))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Biomarker (Neuron Specific Enolase (NSE); MYO 16 (myosin XVI); KIRREL3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weaning outcome from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fall Efficacy Scale International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Altered PTH-related renal active hormonal axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 1-year disease free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in clinESSDAI score at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful recruitment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence rate to the anticoagulation protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale - Agrı
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoxemia events
Endpoint domain: Adverse events/effects
Primary endpoint: eating in the absence of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of vaccine-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any clinically significant clinical laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving ACR 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time to Maximum Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Ginger Muco-bioadhesive Gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Western Aphasia Battery scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With DILI and CHF AEs
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of adverse events/adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for methylone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC: Area under the plasma concentration-time curve for methylone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete closure of Target Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of PRGN-3007 (Group A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of PRGN-3007 (Group B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: safety and tolerability of intratumoral IVX037
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy of intratumoral IVX037 in combination with an intravenous immune checkpoint inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Pfs25IMX313-Matrix-M
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of VOCs in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission after 7 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphoedema-specific Patient Reported Outcome Measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LDL-C reduction of ≥ 50% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: final LDL-C of <1.4 mmol/L (<55 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in UAS7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ISS7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HSS7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of pathologic complete responses (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-brain phase synchronization in Alpha frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-brain phase synchronization in Theta frequency band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incentive spirometry adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Consistency of incentive spirometry adherence throughout postoperative stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective Response Rate (ORR) As Assessed by Investigator Per RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dynamic Push Ups Peak Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Training attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Patients with any Completed Well-Child Visits
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Predefined grade ≥3 relevant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Plasma Concentration (Cmax) of Divarasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Hour 0 to the Last Measurable Concentration (AUC0-t) of Divarasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Divarasib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wrist joint active range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Ashworth scale (MAS) for muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APILHAND-Kids scale for fine motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The quality of life using paediatric Cerebral Palsy Quality of Life (CP QoL) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of AI-EKG test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uptake of cardiac screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Doses Taken as Prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of acute grade ≥3 GI and GU adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants that experienced dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Retention rate of CLL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accurate small bowel length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence and frequency of late-occurring adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitation of tumor hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantitation of proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rates of clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of poor outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Change in depressive symptom severity measured by GRID Hamilton Depression Rating Scale (GRID-HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing